McKesson said revenues for Q4 ended March 31, 2025 were $90.8 billion, an increase of 19%, and diluted earnings per share were $10.01, with Adjusted Earnings per Diluted Share of $10.12, an increase of 64%.

1. 01

   McKesson said revenues for Q4 ended March 31, 2025 were $90.8 billion, an increase of 19%, and diluted earnings per share were $10.01, with Adjusted Earnings per Diluted Share of $10.12, an increase of 64%.

2. 02

   The company said cash flow from operations for the full year was $6.1 billion, and Free Cash Flow, reflecting capital expenditures of $859 million, was $5.2 billion, and it returned $3.5 billion to shareholders.

3. 03

   McKesson announced its intention to separate its Medical-Surgical Solutions segment into an independent company ('NewCo'), and said it anticipates providing more information on the form and timing of the separation as the process progresses.

4. 04

   The company established fiscal 2026 Adjusted Earnings per Diluted Share guidance of $36.75 to $37.55, representing 11% to 14% growth compared to the prior year. McKesson said it does not provide GAAP earnings per diluted share guidance.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.